Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Will Inherit OAI Status Of Andrx' Oral Contraceptives

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA will continue to block approval of Andrx' oral contraceptives until manufacturing issues are resolved despite the company's intention to transfer its pending ANDAs to Teva

You may also be interested in...



Watson boosts generics portfolio from Teva/Barr

Watson will acquire a portfolio of generics being divested as part of the Teva/Barr deal, pending its consummation, for an upfront purchase price of $36 million. The portfolio includes 15 FDA-approved products, notably cyclosporine capsules and liquid; desmopressin tablets; glipizide/metformin tablets; mirtazapine orally disintegrating tablets; and metoclopramide tablets - as well as two in development. Under the terms of the agreement, Watson will make additional payments to Teva as development-stage products progress and obtain the products under a manufacturing and supply agreement from Teva until manufacturing is transferred. The deal does not appear to contain any oral contraceptives, which are among the most coveted assets that Teva and Barr could have to divest (1"The Pink Sheet," Aug. 25, 2008, p. 21). While it remains unclear whether the merger firm will have to pare down its portfolio of OCs, it's unlikely that any would go to Watson, which spun off some of those products to Teva as part of its 2006 acquisition of Andrx (2"The Pink Sheet" DAILY, May 5, 2006)

Watson boosts generics portfolio from Teva/Barr

Watson will acquire a portfolio of generics being divested as part of the Teva/Barr deal, pending its consummation, for an upfront purchase price of $36 million. The portfolio includes 15 FDA-approved products, notably cyclosporine capsules and liquid; desmopressin tablets; glipizide/metformin tablets; mirtazapine orally disintegrating tablets; and metoclopramide tablets - as well as two in development. Under the terms of the agreement, Watson will make additional payments to Teva as development-stage products progress and obtain the products under a manufacturing and supply agreement from Teva until manufacturing is transferred. The deal does not appear to contain any oral contraceptives, which are among the most coveted assets that Teva and Barr could have to divest (1"The Pink Sheet," Aug. 25, 2008, p. 21). While it remains unclear whether the merger firm will have to pare down its portfolio of OCs, it's unlikely that any would go to Watson, which spun off some of those products to Teva as part of its 2006 acquisition of Andrx (2"The Pink Sheet" DAILY, May 5, 2006)

Watson-Andrx Merger Deadline Extended

The closing date for the Watson-Andrx merger is being extended from Sept. 12 to Nov. 13 to allow for "additional time to confer with the FTC," the companies announced July 10

Related Content

Topics

UsernamePublicRestriction

Register

PS064276

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel